A new personalized mRNA melanoma vaccine developed by Moderna and Merck is showing promising results, cutting the risk of cancer recurrence nearly in half for high-risk patients.

Arbutus Biotech (ABUS) heads to a key March Moderna LNP patent trial as imdusiran HBV milestones drive value—get the latest ...

Two and a half years after Sanofi unveiled to investors a revamped strategy to create an mRNA seasonal flu vaccine, Fierce Biotech has learned that the French pharma has put this pipeline on ice.

Phacilitate’s annual event dawns as cell and gene therapies reach a new tipping point: the science has hit new heights just ...

Two of the vaccines we have for COVID-19 have the distinction of being the first mRNA vaccines to see widespread use in humans. But how do they work, and how are they different from all the ...

At the World Economic Forum, CEO Stéphane Bancel expressed concern about the US vaccine market but remained committed to cancer and rare disease mRNA programs.

The University of Auckland is hosting the research as part of the Global COVID Vaccine Safety (GCoVS) Project. Scientists ...

Since the announcements by federal health authorities earlier this year that federal mRNA vaccine funding will be curtailed, a fierce debate has taken place around the future of mRNA-based vaccines ...

mRNA vaccines, such as those used against COVID-19, are effective at generating antibody responses. These antibodies are produced through specialized immune structures called germinal centers, but ...

Heart inflammation caused by the mRNA COVID vaccines is rare. The COVID vaccines have saved millions of lives from a virus that has killed more than seven million people globally. Many safety studies ...